AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39284697
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg daily (after 1 month at 40 mg daily)
Trial: 39285295
Drug: LDL-C levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C levels > 2.6 mmol/L (Groups 3 and 4)
Trial: 39285295
Drug: LDL-C levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C levels ≤ 2.6 mmol/L (Groups 1 and 2)
Trial: 39285313
Drug: Foley catheter
RxNorm normalized name: Bard Foley Catheter 18FR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley catheter balloon combined with oral estrogen therapy
Trial: 39285365
Drug: Psychoeducational programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational programme supplementing Treatment As Usual (TAU)
Trial: 39285418
Drug: Investigational gene
RxNorm normalized name: INVESTIGATIONAL GENE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational gene therapy (resamirigene bilparvovec)
Trial: 39285437
Drug: Ketoprofen (NSAID)
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen (NSAID) 100 mg every 12 hours for 48 hours after surgery
Trial: 39286575
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg sprifermin every 12 months
Trial: 39286575
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg sprifermin every 6 months
Trial: 39286575
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg sprifermin every 12 months
Trial: 39286575
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg sprifermin every 6 months
Trial: 39286636
Drug: LY01610 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY01610 at 60 mg/m²
Trial: 39286636
Drug: LY01610 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY01610 at 80 mg/m²
Trial: 39286890
Drug: Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Therapy (Pulmonary Hypertension Drugs)
Trial: 39287102
Drug: Preoperative assessment
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative assessment of U neutrophil gelatinase-associated lipocalin (NGAL) and liver-type fatty acid-binding protein (L-FABP)
Trial: 39287102
Drug: Combined assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined assessment of U osmolality (OSM), U kidney injury molecule 1 (KIM-1), and tissue inhibitor of metalloproteinase (TIMP-1) within 48 h post-LT
Trial: 39287249
Drug: sugammadex 2
RxNorm normalized name: sugammadex 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugammadex 2 mg/kg (Group S)
Trial: 39287249
Drug: sugammadex 1
RxNorm normalized name: sugammadex 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugammadex 1 mg/kg with neostigmine 20 µg/kg + atropine 10 µg/kg (Group S1N)
Trial: 39287249
Drug: sugammadex 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugammadex 1.5 mg/kg with neostigmine 20 µg/kg + atropine 10 µg/kg (Group S2N)
Trial: 39287249
Drug: sugammadex (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugammadex (both doses) with neostigmine
Trial: 39287566
Drug: First-line protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line protease inhibitor (PI)-based regimen
Trial: 39287606
Drug: Mathematical model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mathematical model predicting relapse probability based on M-protein dynamics and response histories up to 12 months of treatment.
Trial: 39287821
Drug: ABBV-011 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-011 monotherapy (1.0 mg/kg every 3 weeks)
Trial: 39287821
Drug: ABBV-011 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-011 monotherapy (various doses up to 2.0 mg/kg)
Trial: 39287964
Drug: Onradivir 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onradivir 600 mg
Trial: 39287964
Drug: Onradivir 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onradivir 600 mg (mild hepatic impairment)
Trial: 39287964
Drug: Onradivir 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onradivir 600 mg (moderate hepatic impairment)
Trial: 39288373
Drug: Peer Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peer Intervention to Link Overdose survivors to Treatment (PILOT) - a 6-month, PSS-led intervention tailored to each participant's goals to reduce overdose risk behavior.
Trial: 39288373
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) - standard-of-care overdose materials, education, and services provided through the participating EDs.
Trial: 39288528
Drug: PIPAC-OX (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIPAC-OX (90 mg/m2) combined with systemic nivolumab
Trial: 39288781
Drug: Neoadjuvant pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant pembrolizumab (200 mg IV every 3 weeks) plus cisplatin-based chemotherapy followed by 13 cycles of adjuvant pembrolizumab (200 mg IV every 3 weeks)
Trial: 39288781
Drug: Neoadjuvant placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant placebo (IV every 3 weeks) plus cisplatin-based chemotherapy followed by 13 cycles of adjuvant placebo (IV every 3 weeks)
Trial: 39288781
Drug: Neoadjuvant pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant pembrolizumab plus chemotherapy
Trial: 39288781
Drug: Neoadjuvant placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant placebo plus chemotherapy
Trial: 39288844
Drug: Subcutaneous nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous nivolumab (1200 mg every 4 weeks)
Trial: 39288844
Drug: Intravenous nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nivolumab (3 mg/kg every 2 weeks)
Trial: 39289029
Drug: E6742 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6742 100 mg
Trial: 39289029
Drug: E6742 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6742 200 mg
Trial: 39289057
Drug: Esomeprazole/magnesium hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole/magnesium hydroxide 40/350 mg
Trial: 39289057
Drug: Enteric-coated esomeprazole
RxNorm normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated esomeprazole 40 mg
Trial: 39289145
Drug: Osimertinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80 mg daily)
Trial: 39289377
Drug: 20 mcg
RxNorm normalized name: Caverject 20 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mcg single dose of H10ssF vaccine
Trial: 39289377
Drug: 60 mcg
RxNorm normalized name: Aranesp 60 MCG in 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mcg two doses of H10ssF vaccine
Trial: 39289825
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (TU)
Trial: 39289825
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of testosterone therapy (TU) and progressive resistance training (Combo)
Trial: 39290050
Drug: Intravenous interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous interventions (typical care)
Trial: 39290050
Drug: Typical care
RxNorm normalized name: Aqua Care Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical care (intravenous metoclopramide and ketorolac)
Trial: 39290129
Drug: Agent PCB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent PCB
Trial: 39290519
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) for smoking cessation, n = 30, implemented in group-based sessions over an eight-week period
Trial: 39290639
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (Cy) 50 mg/kg with TBI 2 Gy, ATG and fludarabine
Trial: 39290639
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (Cy) 100 mg/kg with TBI 2 Gy, ATG and fludarabine
Trial: 39290639
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (Cy) 0 mg/kg with TBI 2 Gy, ATG and fludarabine
Trial: 39290639
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (Cy) 150 mg/kg with TBI 2 Gy, ATG and fludarabine
Trial: 39290680
Drug: Transcatheter edge-to-edge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter edge-to-edge repair (TEER) with the MitraClip device plus guideline-directed medical therapy (GDMT)
Trial: 39290817
Drug: Mean transvalvular
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean transvalvular pressure gradient to effective orifice area ratio (MG/EOA)
Trial: 39290817
Drug: MG/EOA ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG/EOA ratio
Trial: 39290981
Drug: GSK3326595 400
RxNorm normalized name: Protein arginine methyltransferase 5 inhibitor gsk3326595
DrugBank: Pemrametostat (DB19170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3326595 400 mg once daily
Trial: 39290981
Drug: GSK3326595 300
RxNorm normalized name: Protein arginine methyltransferase 5 inhibitor gsk3326595
DrugBank: Pemrametostat (DB19170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3326595 300 mg once daily
Trial: 39291052
Drug: Anxiolytic drugs
RxNorm normalized name: ANXIOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anxiolytic drugs (alprazolam, bromazepam, lorazepam, meprobamate, midazolam, oxazepam)
Trial: 39291303
Drug: Omalizumab-assisted multi-food
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab-assisted multi-food oral immunotherapy (mOIT)
Trial: 39291502
Drug: Guideline-directed optimal
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed optimal medical therapy (receiving angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and statins)
Trial: 39291867
Drug: Model 2
RxNorm normalized name: Model 2004FAA Model 3-EEMK Model 3-EEMK-1 Model AA-8565 Model AA-8565-LATAM Model AWFAREMK Model CHAUTAUQUAEMK Model emk1000-10 Model FAREMK Model PMONTFAREMK Model SWEEMK Model SWEEMK-1 Model QXEMK Model G4FAREMK Model AA-8565 (excluding Miami Air) KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model 2 (including 2 treatment-related predictors)
Trial: 39291967
Drug: High-dose glucagon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glucagon
Trial: 39292112
Drug: Electro-massage (ES)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-massage (ES) combined with Manual Therapy (MT)
Trial: 39292433
Drug: Donanemab (13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donanemab (13 doses over 1 year)
Trial: 39292927
Drug: Axatilimab 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axatilimab 0.3 mg/kg every 2 weeks
Trial: 39292927
Drug: Axatilimab 1
RxNorm normalized name: Axatilimab
DrugBank: Axatilimab (DB16388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axatilimab 1 mg/kg every 2 weeks
Trial: 39292927
Drug: Axatilimab 3
RxNorm normalized name: Axatilimab
DrugBank: Axatilimab (DB16388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axatilimab 3 mg/kg every 4 weeks
Trial: 39292928
Drug: Pomalidomide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide (4 mg daily for 24 weeks)
Trial: 39292975
Drug: Atezolizumab combined
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib
Trial: 39293214
Drug: vYF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vYF vaccine (4, 5 or 6 Log CCID)
Trial: 39293214
Drug: vYF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vYF vaccine
Trial: 39293214
Drug: YF-VAX vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YF-VAX vaccine
Trial: 39293462
Drug: Open-label, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label, intravenous treatment (specific treatment not mentioned)
Trial: 39293515
Drug: BMS-986365 (CC-94676)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986365 (CC-94676) at doses of 400-900 mg twice daily (n = 60)
Trial: 39293515
Drug: BMS-986365 (CC-94676)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986365 (CC-94676)
Trial: 39293778
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance training (RT) plus bone-loading exercises and placebo capsules
Trial: 39293778
Drug: No RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No RT and placebo capsules
Trial: 39294149
Drug: BWC0977 (Novel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BWC0977 (Novel Bacterial Topoisomerase Inhibitor)
Trial: 39294452
Drug: Polypharmacy (≥8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (≥8 medications)
Trial: 39294452
Drug: Potentially inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially inappropriate medications (≥1 PIM per STOPP)
Trial: 39294522
Drug: Atomoxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (10 or 18 mg)
Trial: 39294797
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave (ESW) therapy
Trial: 39296979
Drug: Prolgolimab 250
RxNorm normalized name: prolgolimab
DrugBank: Prolgolimab (DB16740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolgolimab 250 mg Q3W
Trial: 39296979
Drug: Prolgolimab 1
RxNorm normalized name: prolgolimab
DrugBank: Prolgolimab (DB16740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolgolimab 1 mg/kg Q2W (historical control)
Trial: 39297052
Drug: Rozanolixizumab 7
RxNorm normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rozanolixizumab 7 mg/kg
Trial: 39297691
Drug: PanBio indirect
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PanBio indirect dengue virus immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA)
Trial: 39297745
Drug: Calcineurin inhibitors
RxNorm normalized name: Calcineurin inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin inhibitors (Group A)
Trial: 39297745
Drug: Mammalian target
RxNorm normalized name: Mammalian target of rapamycin (mTOR) kinase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mammalian target of rapamycin inhibitors (sirolimus - Group B)
Trial: 39297839
Drug: 14-day continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day continuous electrocardiogram patch monitor
Trial: 39298147
Drug: Rogaratinib 600
RxNorm normalized name: Rogaratinib
DrugBank: Rogaratinib (DB15078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rogaratinib 600 mg or 800 mg twice daily plus atezolizumab 1200 mg every 21 days
Trial: 39298716
Drug: Palbociclib (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib (75 mg/m² orally once daily for 21 days of 28-day cycles)
Trial: 39298718
Drug: Pembrolizumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab + Radiation Therapy (RT)
Trial: 39299559
Drug: Simnotrelvir/ritonavir co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simnotrelvir/ritonavir co-administered with itraconazole (strong CYP3A and P-gp inhibitor)
Trial: 39299559
Drug: Simnotrelvir/ritonavir co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simnotrelvir/ritonavir co-administered with midazolam (CYP3A substrate)
Trial: 39299559
Drug: Simnotrelvir/ritonavir co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simnotrelvir/ritonavir co-administered with rifampicin (strong CYP3A and P-gp inducer)
Trial: 39299734
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation (OAC) started according to the '1-3-6-12 days rule' in 255 patients (39.2%).
Trial: 39300008
Drug: Oxytocin maintenance
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin maintenance infusion at 4.5 IU·hr
Trial: 39300008
Drug: 1-IU oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-IU oxytocin bolus followed by maintenance infusion
Trial: 39300055
Drug: Calf Circumference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calf Circumference (CC)
Trial: 39300055
Drug: BMI-adjusted CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMI-adjusted CC
Trial: 39300222
Drug: Ibrutinib 140
RxNorm normalized name: ibrutinib 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 140 mg/day
Trial: 39300222
Drug: Ibrutinib 280
RxNorm normalized name: ibrutinib 280 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 280 mg/day
Trial: 39300222
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg/day
Trial: 39300222
Drug: Ibrutinib >560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib >560 mg/day
Trial: 39300376
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (standard arm)
Trial: 39300465
Drug: Standard national
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard national treatment of uncomplicated SAM
Trial: 39300596
Drug: IV secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every four weeks)
Trial: 39300513
Drug: IV secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV secukinumab (3 mg/kg every four weeks after switching from placebo)
Trial: 39300529
Drug: rTMS-active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTMS-active treatment for 10 consecutive days (n=10)
Trial: 39300529
Drug: rTMS-sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTMS-sham treatment for 10 consecutive days (n=10)
Trial: 39300529
Drug: rTMS-active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTMS-active treatment
Trial: 39300596
Drug: IV secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV secukinumab (continued treatment through week 52)
Trial: 39300870
Drug: Strengthening coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strengthening coping strategies and treatment expectations
Trial: 39301110
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (20 µg)
Trial: 39301110
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D insufficiency (<50 nmol/L)
Trial: 39301223
Drug: Blended Trauma-focused
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended Trauma-focused Cognitive Therapy (bTF-CT)
Trial: 39301485
Drug: 0.01% atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% atropine topical eye drop
Trial: 39301593
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care including behavioural and antidepressant therapy (ADT)
Trial: 39302614
Drug: SG 10
RxNorm normalized name: emapalumab-lzsg 10 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SG 10 mg/kg
Trial: 39302982
Drug: CBD-enriched Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD-enriched Cannabis Herbal Extract (MPL-001 with a THC:CBD of 1:25), starting at 0.2-0.4 mg/kg of CBD per day and escalating monthly up to 0.8-1.0 mg/kg of CBD per day
Trial: 39303189
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) with chemotherapy if node-positive